NEUP (Neuphoria Therapeutics) FCF Margin % : -506.49% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neuphoria Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-3.36 Mil. Neuphoria Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.66 Mil. Therefore, Neuphoria Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -506.49%.

As of today, Neuphoria Therapeutics's current FCF Yield % is -41.47%.

The historical rank and industry rank for Neuphoria Therapeutics's FCF Margin % or its related term are showing as below:

NEUP' s FCF Margin % Range Over the Past 10 Years
Min: -8396.88 Med: -410.08 Max: 61.69
Current: -1175.11

During the past 13 years, the highest FCF Margin % of Neuphoria Therapeutics was 61.69%. The lowest was -8396.88%. And the median was -410.08%.

NEUP's FCF Margin % is ranked worse than
78.86% of 1017 companies
in the Biotechnology industry
Industry Median: -142.95 vs NEUP: -1175.11

Neuphoria Therapeutics FCF Margin % Historical Data

The historical data trend for Neuphoria Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics FCF Margin % Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-8,396.88

-8,269.06

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-506.49

Competitive Comparison of Neuphoria Therapeutics's FCF Margin %

For the Biotechnology subindustry, Neuphoria Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's FCF Margin % falls into.

Save

Neuphoria Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neuphoria Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-14.681	/	0
	=	%

Neuphoria Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-3.358	/	0.663
	=	-506.49 %

Neuphoria Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.